Acinetobacter baumannii in critically ill patients: Molecular epidemiology, clinical features and predictors of mortality;Acinetobacter baumannii en pacientes críticos: epidemiología molecular, características clínicas y predictores de mortalidad

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 34, Issue 9, 2016, Pages 551-558

  Garnacho Montero, José ^a,b   Gutiérrez Pizarraya, Antonio ^b,c   Díaz Martín, Ana ^a,b   Cisneros Herreros, José Miguel ^a,b,c   Cano, María Eugenia ^d   Gato, Eva ^d   Ruiz de Alegría, Carlos ^d   Fernández Cuenca, Felipe ^e   Vila, Jordi ^f   Martínez Martínez, Luis ^d,h   Tomás Carmona, M del Mar ^g   Pascual, Álvaro ^c,e   Bou, Germán ^g   Pachón Diaz, Jerónimo ^a,b,c   Rodríguez Baño, Jesús ^c,e  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c Spanish Network for the Research in Infectious Diseases ^*  (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g UNIVERSITY OF A CORUÑA   (Spain)

^h UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Acinetobacter baumannii; Clonality; Infectious diseases; Intensive medicine; Mortality

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; COLISTIN; TIGECYCLINE;

ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CLINICAL FEATURE; COHORT ANALYSIS; CRITICALLY ILL PATIENT; FEMALE; HOSPITAL MORTALITY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; MORTALITY RISK; MULTICENTER STUDY; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PNEUMONIA; PROSPECTIVE STUDY; ACINETOBACTER BAUMANNII; CLINICAL TRIAL; CRITICAL ILLNESS; CROSS INFECTION; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MORTALITY; SPAIN; TIME FACTOR;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; CRITICAL ILLNESS; CROSS INFECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PROSPECTIVE STUDIES; SPAIN; TIME FACTORS;

EID: 84955591537     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2015.11.018     Document Type: Article

References (39)

1. 1 Vincent, J.-L., Rello, J., Marshall, J., Silva, E., Anzueto, A., Martin, C.D., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302 (2009), 2323–2329.
2. 2 Alvarez-Lerma, F., Palomar, M., Olaechea, P., Otal, J.J., Insausti, J., Cerdá, E., et al. National Study of Control of Nosocomial Infection in Intensive Care Units. Evolutive report of the years 2003–2005. Med Intensiva 31 (2007), 6–17.
3. 3 Garnacho-Montero, J., Amaya-Villar, R., Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 23 (2010), 332–339.
4. 4 Cisneros, J.M., Rodríguez-Baño, J., Fernández-Cuenca, F., Ribera, A., Vila, J., Pascual, A., et al. Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect 11 (2005), 874–879.
5. 5 Karageorgopoulos, D.E., Falagas, M.E., Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8 (2008), 751–762.
6. 6 Villalón, P., Valdezate, S., Medina-Pascual, M.J., Rubio, V., Vindel, A., Saez-Nieto, J.A., Clonal diversity of nosocomial epidemic Acinetobacter baumannii strains isolated in Spain. J Clin Microbiol 49 (2011), 875–882.
7. 7 Giannouli, M., Tomasone, F., Agodi, A., Vahaboglu, H., Daoud, Z., Triassi, M., et al. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii strains in intensive care units of multiple Mediterranean hospitals. J Antimicrob Chemother 63 (2009), 828–830.
8. 8 Heo, S.T., Oh, W.S., Kim, S.-J., Bae, I.G., Ko, K.S., Lee, J.C., Clinical impacts of a single clone (sequence type 92) of multidrug-resistant Acinetobacter baumannii in intensive care units. Microb Drug Resist 17 (2011), 559–562.
9. 9 Nutman, A., Glick, R., Temkin, E., Hoshen, M., Edgar, R., Braun, T., et al. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clin Microbiol Infect 20 (2014), O1028–O1034.
10. 10 Rodríguez-Baño, J., Cisneros, J.M., Fernández-Cuenca, F., Ribera, A., Vila, J., Pascual, A., et al. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 25 (2004), 819–824.
11. 11 Villar, M., Cano, M.E., Gato, E., Garnacho-Montero, J., Miguel Cisneros, J., Ruíz de Alegría, C., et al. Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal. Medicine (Baltimore) 93 (2014), 202–210.
12. 12 Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987), 373–383.
13. 13 Mccabe, W.R., Davis, J.C., Andersen, B.R., Jackson, G.G., A critical evaluation of clinical and laboratory studies. N Engl J Med 263 (1960), 927–934.
14. 14 Horan, T.C., Andrus, M., Dudeck, M.A., CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36 (2008), 309–332.
15. 15 Álvarez, F., Torres, A., Rodríguez de Castro, F., Recomendaciones para el diagnóstico de la neumonía asociada a ventilación mecánica. Med Intensiva 25 (2001), 271–282.
16. 16 Levy, M.M., Fink, M.P., Marshall, J.C., Abraham, E., Angus, D., Cook, D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 (2003), 1250–1256.
17. 17 Erbay, A., Idil, A., Gözel, M.G., Mumcuoğlu, I., Balaban, N., Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 34 (2009), 575–579.
18. 18 M100-S22: performance standards for antimicrobial susceptibility testing. 2012 Twenty-Second Informational Supplement-M100S22E.pdf [Internet] http://antimicrobianos.com.ar/ATB/wp-content/uploads/2012/11/M100S22E.pdf.
19. 19 Fernández-Cuenca, F., Tomás-Carmona, M., Caballero-Moyano, F., Bou, G., Martínez-Martínez, L., Vila, J., et al. In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010. Enferm Infecc Microbiol Clin 31 (2013), 4–9.
20. 20 Durmaz, R., Otlu, B., Koksal, F., Hosoglu, S., Ozturk, R., Ersoy, Y., et al. The optimization of a rapid pulsed-field gel electrophoresis protocol for the typing of Acinetobacter baumannii, Escherichia coli and Klebsiella spp. Jpn J Infect Dis 62 (2009), 372–377.
21. 21 Versalovic, J., Koeuth, T., Lupski, J.R., Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res 19 (1991), 6823–6831.
22. 22 Palomar, M., Álvarez-Lerma, F., Riera, A., Díaz, M.T., Torres, F., Agra, Y., et al. Impact of a national multimodal intervention to prevent catheter-related bloodstream infection in the ICU: the Spanish experience. Crit Care Med 41 (2013), 2364–2372.
23. 23 Mezzatesta, M.L., D'Andrea, M.M., Migliavacca, R., Giani, T., Gona, F., Nucleo, E., et al. Epidemiological characterization and distribution of carbapenem-resistant Acinetobacter baumannii clinical isolates in Italy. Clin Microbiol Infect 18 (2012), 160–166.
24. 24 Montero, M., Horcajada, J.P., Sorlí, L., Alvarez-Lerma, F., Grau, S., Riu, M., et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 37 (2009), 461–465.
25. 25 Cai, Y., Wang, R., Liang, B., Bai, N., Liu, Y., Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 55 (2011), 1162–1172.
26. 26 Prasad, P., Sun, J., Danner, R.L., Natanson, C., Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 54 (2012), 1699–1709.
27. 27 Bartual, S.G., Seifert, H., Hippler, C., Luzon, M.A.D., Wisplinghoff, H., Rodríguez-Valera, F., Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol 43 (2005), 4382–4390.
28. 28 Di Popolo, A., Giannouli, M., Triassi, M., Brisse, S., Zarrilli, R., Molecular epidemiological investigation of multidrug-resistant Acinetobacter baumannii strains in four Mediterranean countries with a multilocus sequence typing scheme. Clin Microbiol Infect 17 (2011), 197–201.
29. 29 Agodi, A., Voulgari, E., Barchitta, M., Quattrocchi, A., Bellocchi, P., Poulou, A., et al. Spread of a carbapenem- and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals. J Hosp Infect 86 (2014), 260–266.
30. 30 Mammina, C., Palma, D.M., Bonura, C., Aleo, A., Fasciana, T., Sodano, C., et al. Epidemiology and clonality of carbapenem-resistant Acinetobacter baumannii from an intensive care unit in Palermo, Italy. BMC Res Notes, 5, 2012, 365.
31. 31 Chopra, T., Marchaim, D., Johnson, P.C., Awali, R.A., Doshi, H., Chalana, I., et al. Risk factors and outcomes for patients with bloodstream infection due to Acinetobacter baumannii–calcoaceticus complex. Antimicrob Agents Chemother 58 (2014), 4630–4635.
32. 32 Giannouli, M., Antunes, L.C.S., Marchetti, V., Triassi, M., Visca, P., Zarrilli, R., Virulence-related traits of epidemic Acinetobacter baumannii strains belonging to the international clonal lineages I–III and to the emerging genotypes ST25 and ST78. BMC Infect Dis, 13, 2013, 282.
33. 33 Garnacho-Montero, J., Ortiz-Leyba, C., Fernández-Hinojosa, E., Aldabó-Pallás, T., Cayuela, A., Marquez-Vácaro, J.A., et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 31 (2005), 649–655.
34. 34 Lee, Y.-T., Kuo, S.-C., Yang, S.-P., Lin, Y.-T., Tseng, F.-C., Chen, T.-L., et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 55 (2012), 209–215.
35. 35 Durante-Mangoni, E., Signoriello, G., Andini, R., Mattei, A., De Cristoforo, M., Murino, P., et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57 (2013), 349–358.
36. 36 Aydemir, H., Akduman, D., Piskin, N., Comert, F., Horuz, E., Terzi, A., et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 141 (2013), 1214–1222.
37. 37 López-Cortés, L.E., Cisneros, J.M., Fernández-Cuenca, F., Bou, G., Tomás, M., Garnacho-Montero, J., et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother 69 (2014), 3119–3126.
38. 38 Poulikakos, P., Tansarli, G.S., Falagas, M.E., Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis 33 (2014), 1675–1685.
39. 39 Plachouras, D., Karvanen, M., Friberg, L.E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53 (2009), 3430–3436.